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E-mail address: masatana@kanazawa-med.ac.jp (MFollistatin-related protein (FRP)/follistatin-like 1 (FSTL1) has multi-speciﬁc binding nature espe-
cially with TGF-b superfamily proteins, and thereby modulates organ development. However, its
function in immune systems remains unclear. Previously, we reported FRP interacts with CD14,
which is known to mediate toll-like receptor 4 (TLR4) signaling. Here, we investigated whether
FRP activates TLR4 signaling. Recombinant FRP induced interleukin 6 or interleukin 8 production
from target cells in a CD14- and TLR4-dependent manner. Moreover, similar to lipopolysaccharide
(LPS), FRP induced tolerance to the second LPS stimulation. FRP has the function of evoking innate
immune responses as one of the endogenous TLR4 agonists.
Structured summary of protein interactions:
FRP physically interacts with CD14 by ﬂuorescence-activated cell sorting (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Findings on the immunological activities of FRP began to beFollistatin-related protein (FRP)/follistatin-like 1 (FSTL1) is a
secreted glycoprotein and a member of the follistatin protein
family. FRP binds transforming growth factor b (TGF-b) superfamily
proteins: activin, TGF-b, bone morphogenetic protein 2/4, their
receptors and follistatin [1]. Previously, we andOuchi et al. reported
that DIP2 disco-interacting protein homolog A from Drosophila
(DIP2A) is one of the receptors for FRP [1,2]. Through the interaction
with these molecules, FRP appears to play a role in the regulation of
tissue development or formation.chemical Societies. Published by E
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. Tanaka).reported after our discovery of FRP as one of the target antigens
of autoantibodies in rheumatoid arthritis (RA) [3]. Subsequently,
we reported that serum autoantibodies to FRP were detected in a
substantial proportion of patients with RA, and their appearance
correlated with disease activity. These autoantibodies neutralized
FRP activity and abrogated its suppressive effect on the production
of matrix metalloproteinases (MMPs/Mmps) and prostaglandins
from synovial cells [4]. Administration of recombinant human
FRP to mice with anti-type II collagen antibody-induced arthritis
(CAIA) ameliorated their arthritis and down-regulated Fos, Ets-2,
interleukin 6 (IL-6), Mmp3 and Mmp9 gene expression in their
joint tissue [5]. Le Luduec et al. reported that adenovirus-mediated
systemic administration of FRP to rats with transplanted hearts
improved their allograft survival, and down-regulated IL-6, inter-
leukin 17A and interferon c gene expression in their allografts
[6]. On the contrary, Miyame et al. reported that overexpression
of FRP using an adenoviral vector in mice with collagen-induced
arthritis (CIA) exacerbated their arthritis and promoted the pro-
duction of IL-6, tumor necrosis factor a and interleukin 1b [7]. This
group also reported that administration of FRP-neutralizing
antibodies to CIA mice reduced their arthritis severity [8]. These
inconsistent results prevented us from understanding the deﬁnite
role of FRP in the immune system.lsevier B.V. All rights reserved.
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mediate toll-like receptor 4 (TLR4) signaling, is one of the
FRP-interacting molecules [1]. Therefore, aiming to ﬁnd the immu-
nological function of FRP, we investigated whether FRP could
activate TLR4 signaling.
2. Materials and methods
2.1. Flow cytometry
Cells were incubated with recombinant human FRP with a FLAG
tag (OriGene) or FLAG-tagged bacterial alkaline phosphatase con-
trol protein (Sigma) for 30 min, then stained with APC-conjugated
antibody to CD14 (Biolegend) and FITC-conjugated antibody to
FLAG (Sigma). Stained cells were analyzed on a FACS Calibur (BD).
2.2. Cells and culture reagents
HEK293(293), HT-1080 and NIH-3T3 cells were purchased from
ATCC. 293-hTLR4A-MD2-CD14 cells were purchased from Invivo-
gen. 293-CD14 cells were generated by transfecting 293 with the
plasmid pSPORT2-hCD14 (Thermo Fisher Scientiﬁc). 293-hTLR4-
MD2 cells were generated by transfecting 293 with the plasmid
pDUO-hMD2/TLR4A (Invivogen). Synovial tissue samples from RA
patients were kindly provided by Dr. T. Nakamura (Kyoto
University). This study was approved by the ethics committee of
the Kyoto University Graduate School and Faculty of Medicine.
Reagents used in these in vitro experiments were lipopolysaccha-
rides (LPS; Sigma), Polymixin B (PMB; Nacalai Tesque), Rhodobacter
sphaeroides LPS (RS-LPS; Invivogen), and recombinant human FRP
(OriGene) which has a FLAG tag. Recombinant mouse FRP was pre-
pared by purifying the supernatant of pBMN-mFRP-transfected
HT-1080 cells with anti-FLAG tag antibody beads (WAKO). Con-
taminated endotoxin was measured by Chromogenic LAL Endo-
toxin Assay Kit (GenScript).
2.3. Western blotting
Samples were subjected to SDS–PAGE and transferred to
Immobilon-NC transfer membranes (Millipore). The blots were re-
acted with antibodies to human or mouse FRP (R&D systems) and
detected by HRP-conjugated anti-goat IgG antibody (Invitrogen).
2.4. Cytokine production analyses
3  104 cells were inoculated into the wells of 48-well plates
ﬁlled with 300 ll of Dulbecco’s modiﬁed Eagle’s medium including
10% fetal calf serum and indicated reagents. After 24 h, the culture
medium was collected and assayed by mouse or human IL-6 ELISA
(eBioscience) or human interleukin 8 (IL-8) ELISA (Biolegend).
2.5. Generation of FRP-overexpressing cells
A retrovirus vector pBMN-IRES-EGFP was kindly provided by
Dr. G. Nolan (Stanford University). FLAG-tagged mouse and human
FRP cDNAs were inserted into the multi-cloning site of pBMN-
IRES-EGFP to make pBMN-mFRP and pBMN-hFRP. Production of
retroviruses and their infection to target cells was performed as
previously described [9].
2.6. Mice
C57BL/6 and DBA/1J mice were purchased from Charles River
Laboratories. Mice deﬁcient in TLR4 (TLR4/) were purchased
from Oriental Bio Service. All animal procedures were approved
by the ethics committee on Animal Experimentation of KyotoUniversity. Methods for ectopically FRP-overexpressing T cells
transfer experiments using CIA mice are described in Supplemen-
tary material.
2.7. RNA interference (RNAi) analysis of FRP
The plasmid vector expressing microRNA (miR) against FRP,
pcDNA6.2-GW/EmGFP-miR-FRP, was prepared using a BLOCK-iT
PolII miR RNAi expression vector kit and primers (K4936-00 and
Hmi427737; Invitrogen). FRP knockdown and control cell lines,
SF1/miR-FRP and SF1/miR-lacZ, were established by transfecting
pcDNA6.2-GW/EmGFP-miR-FRP and pcDNA6.2-GW/EmGFP-miR-
lacZ (V49350-00; Invitrogen) into SF1, and selecting them with
Blasticidin (10 lg/ml). The expression levels of FRP gene are eval-
uated by RT-PCR using SYBR Green I (Applied Biosystems). The
primer pairs are described in Supplementary material.
2.8. Induction of LPS tolerance
Two milliliters of ice-cold Hanks’ balanced salt solutions were
injected into abdominal cavities of C57BL/6 mice. After 2 h, these
wash solutions were collected and cells were isolated from them.
These mononuclear cells were stimulated with mouse FRP, human
FRP or LPS. After 24 h, the medium was completely replaced with
fresh medium, and cells were stimulated with LPS for the next
24 h. The cell supernatants were collected and their IL-6 concen-
tration was measured by ELISA.
2.9. Statistics
Each experiment is performed in triplicate or more, and results
are expressed as mean + S.E. A one factor ANOVA, Mann–Whitney
U test or Student’s unpaired t test was performed using Statview
5.0 (SAS Institute Inc.). In all analyses, probability values <0.05
were considered signiﬁcant.3. Results
Interaction of FRP with CD14 was observed also in a cell-based
system using CD14-expressing HEK293 cells (Fig. 1). Then we
examined proinﬂammatory activity of FRP. Human FRP signiﬁ-
cantly induced IL-6 from cultured synovial cells from RA patients
(Fig. 2A). There, maximum concentration of 50 ng/ml was consid-
ered to be about 10-fold average concentration in healthy human
sera [10]. Notably, it was not human but mouse FRP that signiﬁ-
cantly induced IL-6 from NIH-3T3 cells of mouse origin (Fig. 2B).
Thus, both human and mouse FRP substantially induced IL-6 from
tested cells of the same species as the FRP. In these and following
experiments, we used recombinant human and mouse FRP whose
undiluted solutions had little or no endotoxin activity, which was
at most 0.032 EU/ml, equivalent to 0.02 ng/ml LPS.
To assess the proinﬂammatory modulation of FRP in mouse
arthritic disease, we performed ectopically FRP-overexpressing T
cell transfer experiments using CIA mice. The T cells bearing trans-
genes from pBMN-mFRP or pBMN-hFRP substantially secreted
mFRP or hFRP (Fig. 2C). Similar to in-vitro experiments, the mice
receiving mouse, but not human, FRP-producing T cells presented
signiﬁcantly more severe arthritis than those receiving mock-
transferred T cells (Fig. 2D and Supplementary Fig. 1). These results
suggested that both human and mouse FRP could be a proinﬂam-
matory factor in vitro and in vivo in a species-speciﬁc manner.
FRP is produced considerably by synovial cells from patients
with RA [8]. SF-1 is one of the available human synovial cell lines
derived from RA patients, and this transformant actually produces
FRP [4]. We therefore examined whether basal expression of IL-6
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Fig. 1. FRP interacts with cell surface CD14. 293, HEK293 cells. 293-CD14, HEK293 cells expressing human CD14. hFRP, FLAG-tagged recombinant human FRP. BAP, FLAG-
tagged bacterial alkaline phosphatase control protein.
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line SF-1/miR-FRP. FRP mRNA expression levels in SF-1/miR-FRP
decreased to about 20% of that in its control SF-1/miR-lacZ
(Fig. 2E). As expected, IL-6 production from SF-1/miR-FRP was sig-
niﬁcantly lower than that from SF-1/miR-lacZ. Furthermore, not
SF-1/miR-lacZ but SF-1/miR-FRP responded to additional FRP
(Fig. 2F).
We checked the TLR4 dependency of the proinﬂammatory
activity in FRP using splenocytes from wild-type and TLR4/
mice. FRP induced IL-6 from splenocytes from C57BL/6 mice, while
those from TLR4/ mice hardly responded to FRP (Fig. 3A). PMB,
a LPS-neutralizing reagent, did not abrogate IL-6 induction by FRP,
which excluded the possibility of LPS contamination in recombi-
nant FRP. PMB slightly increased FRP activity for some reason,
however similar phenomena were reported on other TLR4-stimu-
lating molecules [11].
Next, we examined CD14 dependency of the proinﬂammatory
activity in FRP using HEK293 and their transformants. Since IL-8
is a better NF-jB activation indicator than IL-6 in HEK293, we mea-
sured IL-8 production from tested cells. FRP and LPS induced IL-8
signiﬁcantly only from 293-hTLR4A-MD2-CD14 (Fig. 3B and
Supplementary Fig. 2). We made sure that FRP actually activated
NF-jB using its reporter system (Supplementary Fig. 3). LPS con-
tamination was excluded by the fact that PMB hardly affected
the FRP activity (Fig. 3C). Interestingly, LPS-RS, a speciﬁc LPS antag-
onist, neutralized the activity of FRP. Although PMB antagonizes
LPS by preventing LPS from binding to CD14, LPS-RS is thought
to compete with LPS for the same binding site on MD2 and to form
inactive complexes with TLR4/MD2 [12]. As shown in Fig. 1, FRP
bound to CD14 on a cell surface. It is probable that after interacting
with CD14 FRP may get translocated to a TLR4/MD2 complex via
binding to MD2.
LPS tolerance is a transient state that is unresponsive to further
challenges of LPS and is considered a protective mechanism againstover inﬂammation. Therefore, we investigated whether FRP in-
duced LPS tolerance. In mouse peritoneal macrophages, 24-hour
exposure to LPS is known to induce complete LPS tolerance [13].
As shown in Fig. 4, both human and mouse FRP brought about a re-
duced response to the second LPS stimulation in inverse proportion
to the ﬁrst response. While cell surface TLR4 expression transiently
decreased roughly according to a degree of tolerance, this effect ap-
peared quite partial to abrogate TLR4 signaling (Supplementary
Fig. 4). This suggests another concomitant mechanism such as im-
paired association of TLR4 with MyD88 [14].
4. Discussion
To date, we have discovered that FRP has two cell signaling
pathways. One is through DIP2A [1,2] and the other is through
CD14 and TLR4, as presented here. In addition to Akt1 phosphory-
lation, the DIP2A pathway mediates FOS down-regulation leading
to the suppression of MMPs and prostaglandins [2,4]. The CD14-
TLR4 pathway mediates the proinﬂammatory reaction. Therefore,
in the physiological reaction to inﬂammation, FRP seems to have
two contradicting activities; one is to prevent tissue destruction
and the other is to promote inﬂammation. Moreover, we found that
FRP has species-speciﬁc activity to TLR4 signaling in target cells be-
tween human and mouse, even though there is at least 91% amino
acid sequence identity between human and mouse FRP. Because
TLR4 signaling needs CD14 and MD2 besides TLR4, species mis-
match for FRP can originate from pairing with all of those
molecules.
At least within the limits of innate immunity, our new results
shown here can deﬁne FRP as a proinﬂammatory factor. They can
also resolve the contradiction raised by our previous CAIA mouse
experiment. In a standard protocol for CAIA induction, LPS was
injected 2-day after the administration of anti-type II collagen
antibody in order to develop arthritis. As we performed daily
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322 K. Murakami et al. / FEBS Letters 586 (2012) 319–324administration of high-dose human FRP (1000 ng/mg of a body),
starting at the same time of antibody administration, FRP was chal-
lenged twice prior to LPS injection. Therefore, we speculate that
human FRP could induce LPS tolerance. On the other hand, theDIP2A pathway was not likely to have been abrogated and could
exert protective functions. As for the induction of allograft toler-
ance by FRP, it is unclear which signaling pathway through DIP2A,
TLR4 or as-yet-unidentiﬁed receptors is involved.
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324 K. Murakami et al. / FEBS Letters 586 (2012) 319–324TLR4 is known to recognize not only various exogenous proteins
from microbes, called pathogen-associated molecular patterns
(PAMPs), but also many endogenous proteins, called damage-asso-
ciated molecular patterns (DAMPs) or ‘‘alarmins’’, such as heat
shock proteins, myeloid-related protein-8/14 (MRP-8/14), surfac-
tant protein A, high-mobility group box 1 (HMGB1), b-defensin
and hyaluronan, which may be expressed or released in response
to tissue damage [15]. In a sense, FRP can be considered as one
of the DAMPs. Notably, HMGB1 is also known to be one of the auto-
antigens in particular autoimmune diseases, such as RA [16].
Besides direct stimulation of TLR4 molecules, DAMPs are
thought to have a sensing function of circulating LPS/PAMPs in
damaged tissues. For example, HMGB1 was shown to associate
with LPS and transfer its monomers to TLR4 molecules on target
cells, thereby enhancing their responsiveness to LPS [17]. Although
it remains to be clariﬁed whether FRP can bind LPS or any PAMPs,
dysregulated FRP production from synovium may play a part in
autoimmune arthritic diseases. It is also possible that impaired tol-
erance to LPS/PAMPs and DAMPs including FRP may be involved.
In conclusion, we revealed that one of the immunological func-
tions of FRP is to evoke innate immune responses through CD14
and TLR4. As FRP has broad physiological activity like TGF-b, vari-
ous approaches will be required to comprehensively elucidate its
unknown functions.
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